Dementia and Geriatric Cognitive Disorders
Original Research Article
The Expression of Presenilin 1 mRNA in Skin Fibroblasts and Brains from Sporadic Alzheimer’s DiseaseIkeda K.a,c · Urakami K.a · Arai H.d · Wada K.a · Wakutani Y.a · Ji Y.a · Adachi Y.a · Okada A.a · Kowa H.a · Sasaki H.d · Ohno K.b · Ohtsuka Y.c · Ishikawa Y.c · Nakashima K.aaDivision of Neurology, Institute of Neurological Sciences, and bDepartment of Neurobiology, Institute of Life Science, Faculty of Medicine, Tottori University, Yonago, cDepartment of Home Economics, Faculty of Education, Tottori University, Tottori, and dDepartment of Geriatric and Respiratory Medicine, Tohoku University School of Medicine, Sendai, Japan
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: August 09, 2000
Issue release date: September – October
Number of Print Pages: 6
Number of Figures: 5
Number of Tables: 1
ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)
For additional information: https://www.karger.com/DEM
Abstract
We examined the expression of presenilin 1 (PS-1) mRNA in cultured skin fibroblasts taken from living patients with Alzheimer’s disease (AD) and human brains taken postmortem from AD patients by RT-PCR analysis. The donors of fibroblasts consisted of 28 cases with AD and 19 neurological patient without dementia (CTL). The brains came from 17 cases with AD and 23 cases with CTL. We found that PS-1 mRNA levels in skin fibroblasts of AD patients were significantly higher than those of CTL patients (p < 0.0001). Moreover, we found that PS-1 mRNA levels in human brains with AD were significantly higher than in those with CTL (p < 0.0001). These findings suggest that high levels of PS-1 mRNA in AD may play an important role in developing AD and that the examination of PS-1 mRNA in skin fibroblasts may be helpful for the diagnosis of AD.
© 2000 S. Karger AG, Basel
Related Articles:
References
- Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin JF, Bruni AC, Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, Pollen D, Brookes A, Sanseau P, Polinsky RJ, Wasco W, Da Silva HAR, Haines JL, Pericak-Vance MA, Tanzi RE, Roses AD, Fraser PE, Rommens JM, St George-Hyslop PH: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 1995;375:754–760.
- Hardy J: Amyloid, the presenilins and Alzheimer’s disease. Trends Neurosci 1997;20:154–159.
- Ikeda K, Urakami K, Isoe K, Ohno K, Nakashima K: The expression of presenilin-1 mRNA in skin fibroblasts from Alzheimer’s disease. Dement Geriatr Cogn Disord 1998;9:145–148.
- Page K, Hollister R, Tanzi RE, Hyman BT: In situ hybridization analysis of presenilin-1 mRNA in Alzheimer disease and in lesioned rat brain. Proc Natl Acad Sci USA 1996;93:14020–14024.
- Cribbs DH, Chen L, Bende SM, LaFerla FM: Widespread neuronal expression of the presenilin-1 early-onset Alzheimer’s disease gene in the murine brain. Am J Pathol 1996;148:1797–1805.
- Nishiyama K, Murayama S, Suzuki T, Mitsui Y, Sakaki Y, Kanazawa I: Presenilin-1 mRNA expression in hippocampi of sporadic Alzheimer’s disease patients. Neurosci Res 1996;26:75–78.
- Johnston JA, Froelich S, Lannfelt L, Cowburn RF: Quantification of presenilin 1 mRNA in Alzheimer’s disease. FEBS Lett 1996;394:279–284.
- Takami K, Terai K, Matsuo A, Walker DG, McGeer PL: Expression of presenilin-1 and presenilin-2 mRNAs in rat and Alzheimer’s disease brains. Brain Res 1997;748:122–130.
-
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Washington, American Psychiatric Association, 1987, pp 103–109.
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease. Neurology 1984;34:939–944.
- Khachaturian ZS: Diagnosis of Alzheimer’s disease. Arch Neurol 1985;42:1097–1105.
-
Ohno K, Takeshita K: Patients with tuberous sclerosis have fibroblasts with normal limits for growth characteristics and sensitivities to DNA alkylating agents. Jpn J Hum Genet 1984;29:359–369.
External Resources
- Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156–159.
- Okada A, Urakami K, Takahashi K, Ohno K, Sato K, Endo H: Expression of amyloid beta-protein precursor mRNAs in cultured skin fibroblasts taken from patients with dementia of the Alzheimer type. Dementia 1994;5:55–56.
- Wolfe MS, Xia WM, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ: Two transmembrane aspartates in presenilin endoproteolysis and gamma-secretase activity. Nature 1999;398:513–517.
- Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S: Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familiar Alzheimer’s disease. Nat Med 1996;2:864–870.
Article / Publication Details
Published online: August 09, 2000
Issue release date: September – October
Number of Print Pages: 6
Number of Figures: 5
Number of Tables: 1
ISSN: 1420-8008 (Print)
eISSN: 1421-9824 (Online)
For additional information: https://www.karger.com/DEM
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
